S

SSY Group Ltd
HKEX:2005

Watchlist Manager
SSY Group Ltd
HKEX:2005
Watchlist
Price: 3.22 HKD 1.9% Market Closed
Market Cap: 9.5B HKD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one SSY Group Ltd stock under the Base Case scenario is 3.77 HKD. Compared to the current market price of 3.22 HKD, SSY Group Ltd is Undervalued by 15%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
3.77 HKD
Undervaluation 15%
Relative Value
Price
S
Worst Case
Base Case
Best Case

Valuation Multiples

1.6
P/S
P/S
Price to Sales
1.6
vs History
93
vs Industry
60
Median 3Y
2
Median 5Y
2.2
Industry
2.4
Forward
1.3
More Details
9
P/E
P/E
Price to Earnings
9
vs History
90
vs Industry
42
Median 3Y
10.8
Median 5Y
12.5
Industry
20.8
Forward
6.8
More Details
12.1
P/OCF
P/OCF
Price to OCF
12.1
vs History
96
vs Industry
32
Median 3Y
14.6
Median 5Y
16.3
Industry
15.4
More Details
44.5
P/FCFE
P/FCFE
Price to FCFE
44.5
vs History
26
vs Industry
12
Median 3Y
28.2
Median 5Y
22.2
Industry
22.8
More Details
1.3
P/B
P/B
Price to Book Value
1.3
vs History
96
vs Industry
52
Median 3Y
1.8
Median 5Y
2.1
Industry
2
More Details
1.9
EV/S
EV/S
Enterprise Value to Sales
1.9
vs History
79
vs Industry
56
Median 3Y
2
Median 5Y
2.2
Industry
2.5
Forward
1.5
More Details
3.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.9
vs History
57
vs Industry
59
Median 3Y
3.6
Median 5Y
3.9
Industry
4.9
More Details
8.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
8.3
vs History
55
vs Industry
42
Median 3Y
7.7
Median 5Y
8.4
Industry
12.7
Forward
5.4
More Details
8.3
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
8.3
vs History
79
vs Industry
44
Median 3Y
8.7
Median 5Y
9.9
Industry
15.8
Forward
6.7
More Details
14.3
EV/OCF
EV/OCF
Enterprise Value to OCF
14.3
vs History
82
vs Industry
30
Median 3Y
14.9
Median 5Y
16.9
Industry
14
More Details
98.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
98.9
vs History
31
vs Industry
5
Median 3Y
44
Median 5Y
62.7
Industry
18.3
More Details
1
EV/IC
EV/IC
Enterprise Value to IC
1
vs History
96
vs Industry
56
Median 3Y
1.3
Median 5Y
1.5
Industry
1.7
More Details

Multiples Across Competitors

Competitors Multiples
SSY Group Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
HK
SSY Group Ltd
HKEX:2005
9.5B HKD 1.6 9 8.3 8.3
US
Eli Lilly and Co
NYSE:LLY
782.6B USD 17.4 73.9 42.9 47.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
399.2B USD 4.5 28.4 13.3 17.4
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK 7.2 20.7 13.6 15.5
CH
Roche Holding AG
SIX:ROG
231.6B CHF 3.9 20.1 11.2 13.3
CH
Novartis AG
SIX:NOVN
198.1B CHF 4.4 18.8 11.4 14.6
UK
AstraZeneca PLC
LSE:AZN
174.5B GBP 4.2 32.1 126.8 193.6
US
Merck & Co Inc
NYSE:MRK
227.3B USD 3.5 13.3 9 10.6
IE
Endo International PLC
LSE:0Y5F
167.6B USD 72.3 -57.3 267.5 670.8
US
Pfizer Inc
NYSE:PFE
143B USD 2.3 17.9 8.5 12.1
P/E Multiple
Earnings Growth PEG
HK
S
SSY Group Ltd
HKEX:2005
Average P/E: 26
9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
73.9
49%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
28.4
26%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
20.7
19%
1.1
CH
Roche Holding AG
SIX:ROG
20.1
16%
1.3
CH
Novartis AG
SIX:NOVN
18.8
16%
1.2
UK
AstraZeneca PLC
LSE:AZN
32.1
36%
0.9
US
Merck & Co Inc
NYSE:MRK
13.3
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -57.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.9
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
HK
S
SSY Group Ltd
HKEX:2005
Average EV/EBITDA: 396.3
8.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
42.9
30%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
13.3
7%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.6
15%
0.9
CH
Roche Holding AG
SIX:ROG
11.2
8%
1.4
CH
Novartis AG
SIX:NOVN
11.4
5%
2.3
UK
AstraZeneca PLC
LSE:AZN
126.8
9%
14.1
US
Merck & Co Inc
NYSE:MRK
9
9%
1
IE
E
Endo International PLC
LSE:0Y5F
267.5
N/A N/A
US
Pfizer Inc
NYSE:PFE
8.5
3%
2.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
HK
S
SSY Group Ltd
HKEX:2005
Average EV/EBIT: 1 700.5
8.3
-5%
N/A
US
Eli Lilly and Co
NYSE:LLY
47.4
33%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
17.4
12%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
15.5
16%
1
CH
Roche Holding AG
SIX:ROG
13.3
9%
1.5
CH
Novartis AG
SIX:NOVN
14.6
8%
1.8
UK
AstraZeneca PLC
LSE:AZN
193.6
21%
9.2
US
Merck & Co Inc
NYSE:MRK
10.6
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
670.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
12.1
10%
1.2

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 242,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.